Comparative Pharmacology
Head-to-head clinical analysis: DEXEDRINE versus METHAMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXEDRINE versus METHAMPEX.
DEXEDRINE vs METHAMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Methamphetamine is a sympathomimetic amine that increases synaptic concentrations of dopamine, norepinephrine, and serotonin by promoting their release from presynaptic terminals and inhibiting their reuptake. It also inhibits monoamine oxidase, reducing neurotransmitter catabolism.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
150 mg orally twice daily for 12 weeks; alternative: 90 mg orally twice daily if tolerability issues.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Terminal elimination half-life is approximately 9-14 hours in adults with normal renal function (mean ~12 hours). In children, half-life is shorter (~8-10 hours). Context: Steady-state is achieved within 2-3 days. Half-life may be prolonged in patients with renal impairment (up to 20-30 hours) or alkaline urine (up to 30 hours).
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Primarily renal excretion (≥90% as unchanged drug and metabolites); approximately 70-80% as unchanged amphetamine, 10-15% as deaminated metabolites (hippuric acid, benzoic acid). Biliary/fecal excretion is negligible (<5%). Renal clearance is pH-dependent; acidic urine increases elimination. In overdose or renal impairment, elimination half-life may prolong.
Category C
Category C
CNS Stimulant
CNS Stimulant